Skip to main content

Table 1 Demographics and clinical characteristics of the study participants

From: Long-term clinical outcomes of catheter ablation in patients with atrial fibrillation predisposing to tachycardia-bradycardia syndrome: a long pause predicts implantation of a permanent pacemaker

Factors n = 121
Age, years old 61.1 ± 10.4
Male, n (%) 64 (52.9)
Longest pause, seconds 5.4 ± 2.4
Time of AF symptom onset, months 36.5 ± 32.3
Type of persistent AF, n (%) 17 (14.0)
AAD before procedure, n (%) 77 (63.6)
 Class I drug 66 (54.5)
 Class III drug 11 (9.1)
Antithrombotic drug, n (%) 109 (90.1)
 Warfarin 45 (37.2)
 Anti-platelet drug 60 (49.6)
 NOAC 4 (3.3)
LVEF 57.8 ± 7.9
LA size, mm 41.0 ± 5.6
E/e′ 9.6 ± 5.2
Hypertension, n (%) 66 (54.5)
Diabetes mellitus, n (%) 16 (13.2)
CHAS2DS2-VASc score 1.9 ± 1.3
 0, n (%) 15 (12.4)
 1, n (%) 39 (32.2)
 ≥ 2, n (%) 67 (55.4)
HAS-BLED score 1.6 ± 1.1
  1. Values are expressed as means±SDs and numbers (percentages). AF atrial fibrillation, AAD anti-arrhythmic drug, NOAC non-vitamin K antagonist anticoagulant, LVEF left ventricular ejection fraction, LA left atrium